摘要
雌、孕激素受体(ER、PR)阳性的浸润性乳腺癌患者,均应接受内分泌治疗。内分泌治疗疗效好,但有其相应的不良反应,骨密度(bone mineral density,BMD)降低是内分泌治疗的主要不良反应之一。本文主要介绍乳腺癌内分泌治疗对患者骨密度的影响方面研究进展。
Endocrine therapy usually should be implemented to invasive breast cancer patients with hormone receptor-positive (ER, PR). Clinical efficacy of endocrine therapy is good, while relvant side effects also exist. The decrease of bone mineral density (BMD) is one of the main side effects in patients receiving endocrine therapy. This paper mainly focuses on the research progress of the effect of endocrine therapy on BMD of patients with breast cancer.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2013年第10期1104-1107,共4页
Chinese Journal of Osteoporosis
关键词
乳腺癌
内分泌治疗
骨密度
双膦酸盐
地诺单抗
Breast cancer
Endocrine therapy
Bone mineral density
Diphosphonates
Denosumab